Trial Profile
A randomized controlled clinical trial to assess the safety and efficacy of RAVICTI in treatment naive patients with urea cycle disorders (UCD)
Status:
Planning
Phase of Trial:
Phase IV
Latest Information Update: 12 Dec 2015
Price :
$35
*
At a glance
- Drugs Glycerol phenylbutyrate (Primary) ; Sodium phenylbutyrate
- Indications Inborn urea cycle disorders
- Focus Adverse reactions; Therapeutic Use
- 12 Dec 2015 New trial record
- 04 Mar 2015 According to the company SEC filing report 10-K 2014, this study is expected to start enrolling in the second half of 2015.